Real-Time Review Is The Most Underrated FDA Story Of The Year

By John Paul (JP) Lee, COO, AG Mednet

The FDA’s new real-time review pilot may be one of the most important changes to clinical operations in decades, and most people are interpreting it too narrowly. While headlines focus on regulators using AI to accelerate review, the deeper shift is operational: the collapse of the traditional boundary between “working” trial data and “submission-ready” data.

Historically, clinical trials have operated on cycles. Data is collected, cleaned, reconciled, locked, and eventually packaged for submission. But the FDA’s pilot, which allows reviewers to access selected trial data as it accrues, changes the premise entirely. If regulators can observe trial data in real time, then sponsors must maintain regulator-ready data continuously.

The real story, then, is not AI. It is an operational architecture. This is precisely the challenge Judi was built to address: enabling a continuously governed, queryable, regulator-ready clinical operations environment. If the FDA expands this pilot over the next several years, sponsors prepared for continuous visibility will have a significant operational advantage.